- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00134420
Growth Hormone and Chromosome 18q- and Abnormal Growth
Growth Hormone Trial for Children With 18q- and Abnormal Growth
Study Overview
Status
Conditions
Detailed Description
HYPOTHESIS:
Our hypothesis with reference to children with 18q deletions who have abnormal growth are:
- growth hormone will improve growth; and
- growth hormone will improve performance IQ (pIQ).
Therefore, our specific aims are to evaluate the impact of GH treatment on:
- linear growth in children with 18q deletions who have abnormal growth but who are not classically growth hormone deficient; and
- pIQ in children with 18q deletions who have abnormal growth
GOALS AND METHODS:
We have already investigated the growth axis in 50 individuals with a cytogenetically and molecularly confirmed 18q deletion by determining the height, growth velocity, insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), bone maturation and growth hormone (GH) response to pituitary stimulants (clonidine and arginine). To summarize: children with 18q deletions are short: 64% have a height more than 2 S.D. below the mean. Affected children also grow slowly: 68% have a growth velocity more than 1 S.D. below the mean. Half of the individuals have delayed bone maturation. Growth factors are skewed downward: 72% of the IGF1 values and 83% of the IGFBP3 values are below the average for normal children. Similarly, 72% of the children failed to adequately respond to the GH stimulants. In the total group of 50 children, 20 (40%) were classically GH DEFICIENT (height <-2 S.D., velocity <-1 S.D., bone age <-2 S.D., IGF1 < -1 S.D., IGFBP3 <-1 S.D., peak GH <10 ng/ml by polyclonal GH assay) and are on GH treatment. Of the remaining 30 children, 28 have multiple abnormalities of the growth axis, primarily growth velocity <-1 S.D. (ABNORMAL GROWTH), but did not qualify for GH treatment according to criteria set by their private insurer. Almost all of these children had abnormalities suggestive of hypothalamic dysfunction involving TSH (thyroid stimulating hormone) and prolactin. None have CNS (central nervous system) abnormalities of the pituitary on MRI. Thus we suspect that many of these children have neurosecretory dysfunction. Parental heights are slightly above average (father (height standard deviation score) HTZ = 0.3 +/- 1.2, mother HTZ = 0.1 +/- 1.1) and none of the children are overweight.
Of 8 children with GHD (growth hormone deficiency) on prolonged GH treatment, growth rates are comparable to those reported by the NCGS (National Collaborative Growth Study) for idiopathic GHD at 1 and 2 years. The mean change in height over a 28-month period for the treated group in our study was +1.8 S.D. while it was -0.25 S.D. in the untreated group (p<0.001). No known complications of GH treatment were encountered. Furthermore, because of an association between 18q deletion, hypomyelination and cognition, some non-statural benefits of GH treatment were examined: specifically, the performance intelligence quotient (pIQ) was measured using a detailed battery of neuropsychological instruments. The pIQ was measured because many of the children are hearing impaired and a full scale IQ, which relies on verbal skills, would underestimate their abilities. The GH-treated group was compared to an untreated group. The GH-treated group (n=8) showed an increase in pIQ of 23 points (range 0 to +47) while the untreated group (n=6) showed no change (range -2 to +6)(p=0.003). Based on these observations, we conclude that GHD children with 18q deletions respond favorably to GH therapy in terms of both linear growth and pIQ. In contrast, children with 18q deletions with abnormal growth who are not classically GH deficient, show little change in height S.D. and pIQ over time. Therefore, we propose to study (NEW STUDY) whether children with 18q deletions with abnormal growth can benefit from GH treatment. For purposes of this proposal, abnormal growth is defined as a growth velocity <-1 S.D.
Initial auxology, endocrine testing, and neurocognitive evaluation will be performed at our Center. Auxologic and neurocognitive testing will be repeated after 18 months of therapy at our Center. These studies are done at our Center to assure consistency of evaluation, which is a particular concern for the neurocognitive tests. Many of the children will also participate in other studies in our Center (MRI imaging, psychological evaluations of family function) that are not part of this application. Children begun on GH treatment will need to be seen by a pediatric endocrinologist for dosage adjustment after 3, 6, 9 and 12 months. The untreated children will also need to be seen by a pediatric endocrinologist for auxologic studies at the same time points. We enrolled 20 children in this study. Few of the children are located in any single geographic area; therefore, we will have 12-20 centers seeing individual children. Rather than developing new forms, standard NCGS intake forms will be used for the intermediate visits by the local pediatric endocrinologists.
Control Group: We have more than 20 previously studied children, 5.3 +/- 2.8 years of age, who have abnormal growth and have never received GH. All have undergone extensive auxologic, hormonal, neurocognitive and neuroimaging evaluations. These studies were done 15.4 +/- 9 months ago (range 11-28 months). We have already shown that, in the absence of intervention, height S.D. and pIQ are stable over time; therefore, these children can serve as their own controls.
We also have 20 children who are GH deficient and on treatment that are participants in another study. These children were evaluated prior to the initiation of treatment. All are scheduled to be re-evaluated at least twice in a five-year period. The data on the first 8 treated children were reported above. These children will serve as important "disease controls".
NAME OF FDA APPROVED DRUG TO BE USED:
We are using Nutropin AQ in this study.
METHOD OF TREATMENT ASSIGNMENT:
All children who have previously been evaluated in our Center were offered the opportunity to receive GH, subject to the following limitations:
- The prior evaluation must have occured at least 12 months preceding the anticipated date of initiation of GH therapy.
- May not be on GH treatment or have been previously treated with GH
- Growth velocity <-1 S.D. with normal weight for length/height
- Must be willing to return to our Center for reevaluation of auxologic parameters and neurocognitive testing prior to the initiation of GH therapy.
- Must be willing to administer GH on a daily basis for 12-15 months
- Must be willing to return to our Center for re-evaluation after 12-15 months of therapy.
The majority of the 20 patients for this study came from the group of children who have been previously evaluated.
New children (families) being seen for their initial visit in our Center, will be offered the opportunity to participate in the clinical trial if they have abnormal growth and are not classically GHD. However, these children will be randomly assigned either to treatment or non-treatment for the initial 12-month period. Both treated and untreated children (families) must comply with limitations 2-6 above.
The minority of the 20 patients for this study came from the group of children who are new.
TYPE OF RANDOMIZATION:
Randomization applied only to children who are new to our Center. When the results of growth factor and GH provocative testing are known, a two-step process will occur. Children, who are GHD, will be started on GH and entered into an on-going study already underway in our Center. They will not qualify for participation in the proposed NEW study. Children who have abnormal growth will be assigned to either the treatment or non-treatment category, using an adaptive randomization scheme to avoid imbalances in the numbers of subjects allocated to the two groups.
PLANNED INTERIM ANALYSIS:
GH-treated children will be seen at 3, 6, 9 and 12 months by their local pediatric endocrinologist for measurement of height and weight, review of medical history and dosage adjustment. Untreated children will be seen at 3, 6, 9, and 12 months for measurement of height and weight and review of medical history.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229-3900
- The University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of chromosome 18 deletion (cytogenetics report)
- Children with abnormal growth but who are not classically growth hormone deficient
Exclusion Criteria:
- Children previously on growth hormone therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Growth Hormone Treatment
Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done 1st for eligibility and this group received GH (growth hormone) (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)immediately after randomization
|
Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
Other Names:
This testing was done to determine growth hormone status prior to starting treatment.
This involved assessment of growth factors such as IGF#1 before treatment was initiated.
This testing was done prior to treatment and at the end of treatment.
|
Other: GH treatment delayed by one year
Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done first for eligibility and this group received growth hormone (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)after one year of observation
|
This testing was done to determine growth hormone status prior to starting treatment.
This involved assessment of growth factors such as IGF#1 before treatment was initiated.
This testing was done prior to treatment and at the end of treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
growth rates 12-15 months after treatment begins
|
Secondary Outcome Measures
Outcome Measure |
---|
performance IQ scores 12-15 months after treatment begins
|
Collaborators and Investigators
Investigators
- Principal Investigator: Daniel E. Hale, M.D., The University of Texas Health Science Center at San Antonio
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Mitosis Modulators
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Sympatholytics
- Clonidine
- Mitogens
Other Study ID Numbers
- 300-C07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth Hormone Deficiency
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in ChildrenIsrael, Denmark, Belgium, Spain, Macedonia, The Former Yugoslav Republic of, Turkey, United Kingdom, France, Slovenia, Czech Republic
-
Novo Nordisk A/SWithdrawnGrowth Hormone Disorder | Growth Hormone Deficiency in Children
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Adult Growth Hormone DeficiencyUnited States
-
Teva Pharmaceutical Industries, Ltd.TerminatedGrowth Hormone-DeficiencyBelarus, Bulgaria, Georgia, Greece, Hungary, Israel, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine
-
OPKO Health, Inc.CompletedSafety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenPediatric Growth Hormone DeficiencyGreece, Hungary, Slovakia
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Delivery SystemsGermany, Netherlands, Sweden
-
OPKO Health, Inc.CompletedAdult Growth Hormone DeficiencyCzechia, Hungary, Israel, Serbia, Slovakia, Slovenia
Clinical Trials on Nutropin AQ
-
Genentech, Inc.Completed
-
University of Texas Southwestern Medical CenterGenentech, Inc.WithdrawnCystic Fibrosis
-
Children's Hospital Los AngelesGenentech, Inc.CompletedGrowth Hormone Deficiency | Hypopituitarism | Septo-Optic DysplasiaUnited States
-
Genentech, Inc.Completed
-
Nationwide Children's HospitalGenentech, Inc.CompletedKidney Failure, Chronic | Renal DialysisUnited States
-
Lundquist Institute for Biomedical Innovation at...TerminatedMucopolysaccharidosis I | Mucopolysaccharidosis II | Mucopolysaccharidosis VIUnited States
-
Genentech, Inc.Completed
-
Northwell HealthRecruitingGrowth | Growth Disorders | Growth Failure | Growth Hormone TreatmentUnited States
-
Genentech, Inc.TerminatedGrowth Hormone DeficiencyUnited States
-
Massachusetts General HospitalGenentech, Inc.CompletedAnorexia Nervosa | Osteoporosis | Osteopenia | Eating DisordersUnited States